A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors

Investigational New Drugs

Volumn 30, Issue 1, 2012, Pages 327-334

  Naing, Aung ^a   Razelle Kurzrock, ^a   Adams, Laurel M ^b   Kleha, Joseph F ^b   Laubscher, Kevin H ^b   Bonate, Peter L ^b   Weller, Steven ^b   Fitzgerald, Colleen ^b   Xu, Yanmei ^b   LoRusso, Patricia M ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b GLAXOSMITHKLINE   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Foretinib; MET; Phase I Trial

Indexed keywords

BISPHOSPHATE SALT; FORETINIB; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ACNE; ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASCITES; BACTEREMIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAILURE TO THRIVE; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOMAGNESEMIA; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; SPINAL CORD COMPRESSION; STEADY STATE; TABLET FORMULATION; THROMBOCYTOPENIA; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANILIDES; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DIPHOSPHATES; DRUG COMPOUNDING; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; QUINOLINES; TABLETS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856540747     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9536-x     Document Type: Article

References (18)

1. Qian F, Engst S, Yamaguchi K et al (2009) Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 69:8009-8016
2. Bean J, Brennan C, Shih J-Y et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104:20932-20937
3. Comoglio PM, Boccaccio C (1996) The HGF receptor family: Unconventional signal transducers for invasive cell growth. Genes Cells 1:347-354 (Pubitemid 126673131)
4. Cui JJ (2007) Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications. Expert Opin Ther Patents 17:1035-1045 (Pubitemid 47610952)
5. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) MET, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925 (Pubitemid 37493640)
6. Ma PC, Kijima T, Maulik G et al (2003) c-MET mutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63:6272-6281 (Pubitemid 37255174)
7. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207-2214
8. Benvenuti S, Comoglio PM (2007) The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 213:316-325 (Pubitemid 47509708)
9. Holmes K, Roberts OL, Thomas AL, Cross MJ (2007) Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19:2003-2012 (Pubitemid 47354167)
10. Bottaro DP, Liotta LA (2003) Out of air is not out of action. Nature 423:593-595 (Pubitemid 36713206)
11. Xin X, Yang S, Ingle G et al (2001) Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 158:1111-1120 (Pubitemid 32221803)
12. Kim ES, Salgia R (2009) MET pathway as a therapeutic target. J Thorac Oncol 4:444-447
13. Rini BI (2007) Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: Current status and future directions. Clin Cancer Res 13:1098-1106 (Pubitemid 46424048)
14. Eder JP, Shapiro GI, Appleman LJ et al (2010) A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 16(13):3507-3516
15. LoRusso P, Eder JP, Sherman L et al (2009) Angiogenesis and Antiangiogenesis Agents: Final results of a phase I dose escalation study of the safety and pharmacokinetics of foretinib administered orally daily to patients with solid tumors. Mol Cancer Ther 8(12 Suppl):A8
16. Jhawer M, Kindler H, Wainberg Z et al (2009) Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/ VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings Post- Meeting Edition Vol 27, No 15 S (May 20 Supplement):4502
17. Srinivasan R, Linehan WM, Vaishampayan U et al (2009) A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC). Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings Post-Meeting Edition Vol 27 (15 S) (May 20 Supplement), 5103
18. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2:205-216 (Pubitemid 30099779)